Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab

• Verfasst von: Martens, Alexander [VerfasserIn]
• Verfasst von: Hassel, Jessica C. [VerfasserIn]
• Titel: Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab
• Verf.angabe: Alexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, Jianda Yuan, Michael A. Postow, Phillip Wong, Emanuela Romano, Amir Khammari, Brigitte Dreno, Mariaelena Capone, Paolo A. Ascierto, Anna Maria Di Giacomo, Michele Maio, Bastian Schilling, Antje Sucker, Dirk Schadendorf, Jessica C. Hassel, Thomas K. Eigentler, Peter Martus, Jedd D. Wolchok, Christian Blank, Graham Pawelec, Claus Garbe, and Benjamin Weide
• Umfang: 11 S.
• Fussnoten: Gesehen am 18.12.2018
• Titel Quelle: Enthalten in: Clinical cancer research
• Jahr Quelle: 2016
• Band/Heft Quelle: 22(2016), 12, S. 2908-2918
• ISSN Quelle: 1557-3265
• DOI: doi:10.1158/1078-0432.CCR-15-2412
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1585629375

Abstract

Purpose: To identify baseline peripheral blood biomarkers associated with clinical outcome following ipilimumab treatment in advanced melanoma patients. Experimental design: Frequencies of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), serum lactate dehydrogenase (LDH), routine blood counts, and clinical characteristics were assessed in 209 patients. Endpoints were overall survival (OS) and best overall response. Statistical calculations were done by Kaplan-Meier- and Cox-regression-analysis including calibration and discrimination by C-statistics. Results: Low baseline LDH, absolute monocyte counts (AMC), Lin−CD14+HLA-DR−/low-MDSC frequencies, and high absolute eosinophil counts (AEC), relative lymphocyte counts (RLC), and CD4+CD25+FoxP3+-Treg frequencies were significantly associated with better survival, and were considered in a combination model. 43.5% of patients presenting with the best biomarker signature had a 30% response rate and mediansurvival of 16 months. In contrast, patients with the worst biomarkers (27.5%) had only a 3% response rate and median survival of 4 months. The occurrence of adverse events correlated with neither baseline biomarker signatures nor the clinical benefit of ipilimumab. In another model, limited to the routine parameters LDH, AMC, AEC, and RLC, the number of favorable factors (4 vs. 3 vs. 2-0) was also associated with OS (p<0.001 for all pairwise comparisons) in the main study and additionally in an independent validation cohort. Conclusions: A baseline signature of low LDH, AMC and MDSCs as well as high AEC, Tregs and RLC is associated with favorable outcome following ipilimumab. Prospective investigation of the predictive impact of these markers following ipilimumab and other treatments, e.g. PD-1 antibodies, is warranted.